AREVA Forms Subsidiary To Develop New Cancer Treatments
May 08, 2009
AREVA, with support of AEC Partners, announced today the formation of AREVA Med LLC, a company focused on the development of powerful new anti-cancer treatments, including the radio-therapeutic agent, lead-212. If proven successful in clinical trials, these new treatments would be used in advanced types of nuclear medicine, such as alpha radio-immunotherapy, for the treatment of aggressive forms of cancer.
“AREVA Med represents the synthesis of decades of experience in nuclear energy and our company’s long-term commitment to sustainable business approaches, including recycling nuclear materials that could prove beneficial in new applications,” said Jacques Besnainou, President of AREVA Inc.
AREVA Med is dedicated to targeting types of cancer that today have limited treatment options and will be able to participate in the development of new treatments for top oncology centers worldwide.
“The formation of AREVA Med is timely because, after considerable effort, we now can produce significant quantities of a new medical-grade isotope, a highly purified lead-212, for research and future treatment applications. Moreover, we have formed valuable partnerships with top-level entities and experts in the United States,” said AREVA Med President and CEO Patrick Bourdet.
AREVA signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute in June 2008 to develop a new cancer treatment using lead-212.